Stockreport

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an a [Read more]